WASHINGTON, D.C. (February 11, 2020)—This week, AdvaMed President and CEO, Scott Whitaker, and AdvaMed CFO and Executive Director of AdvaMed Advance, Jennifer Brearey, co-authored an editorial outlining steps the medical technology industry is taking to cultivate more diverse, more inclusive workplace cultures.
Whitaker and Brearey wrote, “To figure out what will support, promote and expand diverse leadership, medtech industry advocates have collaborated to map out ‘what ideal looks like’ in the context of inclusion and diversity. We’ve contemplated how organizations mature along the continuum of inclusion and diversity standards to become industry models. We’ve found that before companies can successfully integrate inclusion and diversity into their business practices, they must first integrate inclusion and diversity into their leadership vision. Holistic change will happen from the top down.”
The editorial will appear in print in several national markets, including New York, Chicago, D.C./Baltimore, Los Angeles, Houston, Seattle and Philadelphia, and will be distributed at the World Health Care Congress, the American Association of Physician Liaisons Conference, and the HLTH Conference. It is the latest in a series of actions the industry has taken to prioritize inclusion and diversity efforts.
In 2019, AdvaMed launched AdvaMed Advance, an initiative created to convene industry leaders and support the creation, maintenance and expansion of inclusion and diversity strategies within the medical technology community.
In January 2020, Scott Whitaker signed the CEO Action for Diversity and Inclusion pledge with AdvaMed Board Chairman Kevin Lobo, CEO of Stryker, Martha Shadan, Chair of AdvaMed’s Diversity and Inclusion Committee and CEO of Miach Orthopaedics, and Jennifer Brearey, Chief Financial Officer and Executive Director of AdvaMed’s inclusion and diversity programs, including AdvaMed Advance and AdvaMed’s Women’s Executive Network.
For more information on AdvaMed’s inclusion and diversity programs, visit AdvaMed Advance.